NVO - Alnylam discovery of genetic mutations could lead to therapies for diabetes obesity
- Recent research for Alnylam Pharmaceuticals ( NASDAQ: ALNY ) that found rare mutations in a gene expressed in the liver and related to body mass index ( BMI ) could spur development of new treatments for metabolic disorders.
- Data and analytics company GlobalData wrote that "a drug which holds a capacity to demonstrate high efficacy in targeting INHBE expression will gain a significant market share as it could help in reducing the risk significantly for multiple metabolic disorders."
- GlobalData noted that Alnylam ( ALNY ) plans to use its RNAi platform to develop a pipeline candidate that targets INHBE and Activin E, a secreted peptide.
- GlobalData Pharma Analyst Akash Patel wrote that the market for type 2 diabetes and obesity treatments has soared led by Novo Nordisk's ( NVO ) Rybelsus and Ozempic (semaglutide) and Eli Lilly's ( LLY ) Mounjaro (tirzepatide)
- Mounjaro "will likely be prescribed in combination with other therapies to address additional cardiorenal problems and will progress to becoming a leading GIP/GLP-1 therapy," Patel added.
- Seeking Alpha's Quant Rating views Alnylam ( ALNY ) as a hold with high grades for momentum and profitability .
For further details see:
Alnylam discovery of genetic mutations could lead to therapies for diabetes, obesity